Our history
Ambusol AB is a Swedish medical technology company founded in 2023 with one clear vision: to transform cancer treatment and improve patient survival and quality of life.
The company is built on more than five decades of pioneering research led by Professor Emeritus Gunnar Ronquist and his team. Their groundbreaking discoveries in cancer biology and medical technology form the foundation of Ambusol’s innovative therapeutic platform.
The origins of Ambusol trace back to the 1970s, when Professor Ronquist began exploring new ways to understand and disrupt cancer at a cellular level. Over the years, this research accumulated into more than 225,000 hours of scientific work, supported by 35 PhD students and multiple international collaborations.
These decades of dedication led to the invention of Ambusol’s unique treatment method – combining an artificial amino acid with a patented catheter system to selectively destroy glioblastoma cells while protecting healthy brain tissue.
At Ambusol, we are dedicated to developing therapies that are not only effective but also non-toxic and humane. We believe cancer treatment should not come at the cost of patient dignity or quality of life.
While our initial focus is on glioblastoma – one of the deadliest forms of brain cancer – our platform has the potential to address other cancers including pancreatic, prostate, breast, and skin cancers. Our goal is to establish Ambusol as a global leader in next-generation oncology therapies.